Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 9/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104788 | 1.00 | ACSS2 (0.42) | ACSS2RORCALDH1A1HPGDKDM4E | |
| SCHEMBL25367234 | 0.88 | ACSS2 (0.43) | ACSS2RORCALDH1A1HPGDKDM4E | |
| SCHEMBL25369178 | 0.87 | ACSS2 (0.53) | ACSS2RORC | |
| SCHEMBL25369467 | 0.86 | ACSS2 (0.54) | ACSS2ALDH1A1HPGDKDM4EAGTR1 | |
| SCHEMBL30104815 | 0.83 | HTR2A (0.37) | ACSS2ALDH1A1 | |
| SCHEMBL23832153 | 0.83 | HTR2A (0.37) | ACSS2ALDH1A1 | |
| SCHEMBL23843513 | 0.82 | ACSS2 (0.46) | ACSS2HPGDKDM4E | |
| SCHEMBL30640969 | 0.82 | ACSS2 (0.46) | ACSS2HPGDKDM4E | |
| SCHEMBL23832307 | 0.82 | ACSS2 (0.64) | ACSS2ALDH1A1HPGDKDM4E | |
| SCHEMBL25367861 | 0.79 | ACSS2 (0.40) | ACSS2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | claimed |
| EP-4121429-B1 | CONDENSED PYRIDINE DERIVATIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-08-13 | — | — | EP | disclosed |
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| EP-4121429-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | Merck Patent GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021185789-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021185789-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | ACSS2 201/4885RORC 1847/4885ALDH1A1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.